# Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Source: https://onco.cc/trials/nct03878849/  
OnCo record `nct03878849` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of 2X-121 in ovarian cancer, run by Allarity Therapeutics, now recruiting.

## Summary

Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer is a phase 2 interventional study registered as NCT03878849 by Allarity Therapeutics, with 40 participants planned, started 2019-04-15 and due to reach its primary completion in 2027-03. Interventions recorded: 2X-121.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03878849
- Phase: 2
- Setting: Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti- Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer.
- Sponsor: Allarity Therapeutics
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT03878849: https://clinicaltrials.gov/study/NCT03878849

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/nct03878849.json